Longitudinal Outcomes in a Cohort of Ugandan Children Randomized to Artemether-Lumefantrine Versus Dihydroartemisinin-Piperaquine for the Treatment of Malaria | Zendy

Humphrey Wanzira | Zendy; Abel Kakuru | Zendy; Emmanuel Arinaitwe | Zendy; Victor Bigira | Zendy; Mary Muhindo | Zendy; Melissa D. Conrad | Zendy; Philip J. Rosenthal | Zendy; Moses R. Kamya | Zendy; Jordan W. Tappero | Zendy; Grant Dorsey | Zendy

Open Access

Longitudinal Outcomes in a Cohort of Ugandan Children Randomized to Artemether-Lumefantrine Versus Dihydroartemisinin-Piperaquine for the Treatment of Malaria

Author(s) -

Humphrey Wanzira,

Abel Kakuru,

Emmanuel Arinaitwe,

Victor Bigira,

Mary Muhindo,

Melissa D. Conrad,

Philip J. Rosenthal,

Moses R. Kamya,

Jordan W. Tappero,

Grant Dorsey

Publication year - 2014

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciu353

Subject(s) - artemether/lumefantrine , piperaquine , malaria , medicine , lumefantrine , artemether , dihydroartemisinin , incidence (geometry) , randomized controlled trial , artemisinin , pediatrics , plasmodium falciparum , immunology , mathematics , geometry

Artemisinin-based combination therapy (ACT) has become the standard of care for the treatment of uncomplicated Plasmodium falciparum malaria. Although several ACT regimens are approved, data guiding optimal choices of ACTs are limited. We compared short- and long-term outcomes in a cohort of young Ugandan children randomized to 2 leading ACTs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research